Skip to main content

Month: May 2024

CorMedix Inc. to Participate in Two Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., May 10, 2024 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in fireside chats and investor meetings at both the JMP Securities Life Sciences Conference being held in New York on May 13 – 14, 2024 and the 2024 RBC Capital Markets Global Healthcare Conference being held in New York on May 14 – 15, 2024. Details for each fireside chat are as follows:JMP Securities Life Sciences ConferenceDate:   Tuesday, May 14, 2024Time:   9:30am EDTWebcast:   Click here     RBC Capital Markets Global Healthcare ConferenceDate:   Wednesday, May 15, 2024Time:   1:35pm EDTWebcast:   Click here     A replay...

Continue reading

Flywire to Attend Upcoming Investor Conferences

BOSTON, May 10, 2024 (GLOBE NEWSWIRE) — Flywire Corporation (Nasdaq: FLYW)(“Flywire” or the “Company”) a global payments enablement and software company, today announced that the Company’s management team will be attending the following upcoming investor conferences:On Tuesday, May 21, 2024, the Company will attend the J.P. Morgan Technology, Media & Communications Conference in Boston, MA. They will participate in a fireside chat discussion which will begin at 4:25pm ET. On Wednesday, June 5, 2024, the Company will attend the William Blair Growth Conference in Chicago, IL. They will participate in a fireside chat discussion which will begin at 2:40pm CT. On Monday, June 10, 2024, the Company will attend the Morgan Stanley US Financials, Payments & CRE Conference in New York, NY. They will participate...

Continue reading

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates

– Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201– Clinically meaningful tumor reduction observed at every belrestotug + dostarlimab dose vs monotherapy– GSK to provide update on GALAXIES program at upcoming investor event in June– RA Capital and Boxer Capital led $120 million registered direct offering at $17.50, representing a premium of approximately 44% to last close– Pro forma cash and investment balance of $715 million as of March 31, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones WATERTOWN, Mass. and GOSSELIES, Belgium, May 10, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company...

Continue reading

Telos Corporation Announces First Quarter Results Above Guidance: Reports $29.6 Million of Revenue, 37.0% GAAP Gross Margin, and 42.2% Cash Gross Margin

Reports First Quarter Results Above High End of Guidance Range on Key Financial Metrics Delivered $29.6 Million of Revenue, Reflecting Outperformance by Security Solutions Generated 37.0% GAAP Gross Margin; Expanded Cash Gross Margin by 249 Basis Points to 42.2% Cash Flow From Operations Was a Modest $0.4 Million Outflow; Free Cash Flow Improved Year-Over-Year Revenues Expected to Return to Sequential Growth in the Third or Fourth Quarter of 2024, Subject to Favorable Resolution of Protests on Typical TimetableASHBURN, Va., May 10, 2024 (GLOBE NEWSWIRE) —  Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced financial results for the first quarter of 2024. “I am pleased to report Telos exceeded the high end...

Continue reading

Whitestone REIT Urges Shareholders to Support Its Highly Qualified Trustee Nominees at the Annual Meeting on May 14 – Vote Today Using the White Proxy Card

Whitestone’s Turnaround Strategy Has Been Successful Under New Board / Leadership Team Our Reset Strategy Has Momentum and the Market Is Recognizing Our Accomplishments Do Not Let Erez Interrupt Our Momentum, Derail Our Strategy and Destroy Value Glass Lewis and Egan Jones, Two Leading Proxy Advisory Firms, Both Recommended that Shareholders Vote “FOR ALL” of Whitestone’s Board Nominees on the WHITE Proxy Card HOUSTON, May 10, 2024 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE:WSR) (“Whitestone” or the “Company”) today announced that it has issued a letter to shareholders related to the upcoming 2024 Annual Meeting of Shareholders scheduled to be held on May 14, 2024. The letter urges shareholders to vote the WHITE proxy card “FOR ALL” of Whitestone’s highly qualified trustees standing for election. The...

Continue reading

Ekso Indego Personal to be Featured on ‘Health Uncensored’ with Dr. Drew Pinsky

Segment to appear on Fox Business News on Sunday, May 12 at 5:30 p.m. ET SAN RAFAEL, Calif., May 10, 2024 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced the Ekso Indego Personal will be featured on ‘Health Uncensored’ hosted by Dr. Drew Pinsky. The episode is scheduled to air on the Fox Business News channel on Sunday, May 12 at 5:30 p.m. ET / 2:30 p.m. PT. Scott Davis, Chief Executive Officer of Ekso Bionics, Michael Glover, Director of Clinical Operations of Ekso Bionics, and Jim Gritton, an Ekso Indego Personal device user, will join Dr. Drew to share the user reported benefits and advanced technology of the Ekso Indego Personal, a powered exoskeleton that is designed to provide patients...

Continue reading

Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD

MORRISVILLE, N.C., May 10, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) announced today the company will present data related to the investigational use of L606 (liposomal treprostinil) inhalation suspension in people with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, California. Rajeev Saggar, MD, chief medical officer at Liquidia, said: “We are pleased to be presenting initial data on the safety and tolerability of L606 from our on-going, open-label study in the United States. We believe that the initial data supports our continued confidence that twice-daily dosing is tolerable, titratable and supports further investigation as we...

Continue reading

Doman Building Materials Group Ltd. Announces Meeting Results for Election of Directors

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, May 10, 2024 (GLOBE NEWSWIRE) — Doman Building Materials Group Ltd. (“Doman”) or the “Company”) (TSX:DBM) announced its director election results following its annual and special meeting of shareholders, held May 9, 2024. All of the nominees proposed as directors in the Company’s Management Information Circular, dated March 22, 2024, were elected on a vote by show of hands. In total 33,931,707 shares were represented in person or by proxy at the meeting, representing approximately 38.9% of the outstanding shares as of the record date of March 18, 2024. The proxies received by management for the election of directors were as...

Continue reading

Smart for Life to Attend Vitafoods Europe 2024: Positioned to Identify Strategic Partnerships and Potential Acquisitions

Renowned Industry Leader and Smart for Life Board Member Heather Granato to Speak at Nutraceutical Event in Geneva, Switzerland MIAMI, May 10, 2024 (GLOBE NEWSWIRE) — Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a distinguished leader in the Health & Wellness sector specializing in the marketing and manufacturing of nutritional supplements and foods, today announced its participation in Vitafoods Europe 2024, scheduled to take place in Geneva, Switzerland from May 14 to 16, 2024. Vitafoods Europe is a premier event in the nutraceutical industry, typically attracting over 25,000 industry experts, and is renowned for its spotlight on the latest advancements and trends shaping the future of health and wellness. Smart for Life’s presence at Vitafoods Europe signifies a meaningful opportunity for...

Continue reading

Mobile-health Network Solutions Expands Services to Malaysia

SINGAPORE, May 10, 2024 (GLOBE NEWSWIRE) — Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth provider, today announced the establishment of a subsidiary in Malaysia. This strategic expansion signifies MNDR’s commitment to delivering accessible and affordable healthcare services throughout Southeast Asia. Solidifying Regional Leadership The Malaysian subsidiary marks a pivotal step in the Company’s growth trajectory. It positions the Company as a frontrunner in telemedicine solutions across Southeast Asia, enabling MNDR to cater to the region’s evolving healthcare needs. This expansion fosters wider patient reach and brand recognition, solidifying the Company’s position as a leader in the burgeoning telemedicine landscape. Tailored Service Offerings The...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.